“WHEREAS Civil Action Nos. 3:24-cv-04314 (MAS), 3:24-cv-00850 (MAS), and 3:24-cv-10236 (MAS) have been brought by Intra-Cellular Therapies, Inc. ("ITCI") against Dr. Reddy’s Laboratories Inc. and Dr. Reddy’s Laboratories Ltd. ("DRL") alleging infringement of United States Patent Nos. RE48,839, 9,168,258, 9,616,061, 10,117,867, 8,648,077, 9,199,995, RE48,825, 10,464,938, 9,956,227, 10,960,009, 11,026,951, 11,753,419, 11,980,617, 12,070,459,12,090,155, 12,128,043, 12,122,792, 12,409,176, and 12,410,195 (collectively, "the Patents-in- Suit"); 1. 2. WHEREAS ITCI currently markets in the United States pursuant to New Drug Application No. 209500 a drug product containing Lumateperone under the trade name Caplyta® ("Caplyta Product"); WHEREAS DRL filed or caused to be filed Abbreviated New Drug Application ("ANDA") No. 219229 seeking FDA approval to make, sell, offer for sale, use, and/or import in or for the United States a pharmaceutical product asserted to be bioequivalent to the Caplyta Product ("DRL ANDA Product"); WHEREAS ITCI and DRL have resolved this litigation for the Patents-in-Suit as to DRL for good cause and valuable consideration recognized by ITCI and DRL; WHEREAS ITCI and DRL respectfully request that the Court terminate the pending litigation as between ITCI and DRL by the entry of this Judgment and Order; and WHEREAS ITCI and DRL now consent to this Judgment and Order. IT IS ORDERED, ADJUDGED AND DECREED as follows: This District Court has jurisdiction over the subject matter of the above action and has personal jurisdiction over the parties. DRL admits for the limited purpose of resolving the pending Action, and with respect to the DRL Product only, that the claims of the Patents-in-Suit are valid and enforceable and one or more claims thereof would be infringed by the commercial manufacture, use, sale, offer for sale, or importation of the DRL Product in the United States prior to the expiration of the Patents-in-Suit. DRL and its affiliates are hereby enjoined from manufacturing, using, offering for sale, selling in the United States, or importing into the United States, the DRL.ANDA Product until the expiration of the Patents-in-Suit, including any patent term extensions and/or patent term adjustments and during the period of any associated pediatric exclusivity, other than as authorized by ITCI. All affirmative defenses, claims and counterclaims, which have been or could have been raised by ITCI against DRL and its affiliates, or by DRL and its affiliates against ITCI, in this litigation solely with respect to the Patents-in-Suit as asserted against the DRL ANDA Product are hereby dismissed with prejudice. ITCI and DRL shall bear their own fees and costs in connection with this litigation, including attorneys’ fees. ITCI and DRL waive all right to appeal or otherwise move for relief from this Judgment and Order. This Court shall retain jurisdiction of this litigation and over ITCI and DRL for purposes of enforcement of the provisions of this Judgment and Order.”